SPA
BCRX icon

Sherbrooke Park Advisers’s BioCryst Pharmaceuticals BCRX Stock Holding History

Sherbrooke Park Advisers’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16,524
Closed -$125K – 224
2025
Q3 		$125K Buy
16,524
+3,866
+31% +$32.2K 0.06% 432
2025
Q2 		$113K Buy
+12,658
New +$118K 0.05% 450
2025
Q1 		– Sell
-34,628
Closed -$260K – 619
2024
Q4 		$260K Buy
34,628
+7,134
+26% +$54.2K 0.08% 467
2024
Q3 		$209K Buy
+27,494
New +$209K 0.05% 736
2024
Q2 		– Sell
-78,814
Closed -$400K – 913
2024
Q1 		$400K Buy
78,814
+66,051
+518% +$371K 0.08% 443
2023
Q4 		$76.5K Buy
+12,763
New +$74K 0.04% 419

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.58B AUM 138.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $121B AUM 33.93% 1-Year Est. Return